Improving cancer treatment with cyclotron produced radionuclides. Progress report

Technical Report · Mon Nov 01 00:00:00 EST 1993

DOI:https://doi.org/10.2172/10118877· OSTI ID:10118877

Larson, S M; Finn, R D

This report describes our continuing long term goal of promoting nuclear medicine applications by improving the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The program includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. An essential strategy is as follows: novel radionuclides and radiotracers developed in the Radiochemistry/Cyclotron section will be employed in the Pharmacology and Immunology sections during the next year. The development of novel radionuclides and tracers is of course useful in and of itself, but their utility is greatly enhanced by the interaction with the immunology and pharmacology components of the program.

• Research Organization: Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
• Sponsoring Organization: USDOE, Washington, DC (United States)
• DOE Contract Number: FG02-86ER60407
• OSTI ID: 10118877
• Report Number(s): DOE/ER/60407-T2; ON: DE94006027; BR: HA0207010/KP0601000
• Resource Relation: Other Information: PBD: 1 Nov 1993
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY
RADIOPHARMACEUTICALS
CHEMICAL PREPARATION
NUCLEAR MEDICINE
CYCLOTRONS
CARBON 11
FLUORINE 18
IODINE 124
GALLIUM 66
DOSIMETRY
POSITRON COMPUTED TOMOGRAPHY
IMMUNOGLOBULINS
PATIENTS
PROGRESS REPORT
550604
550601
400703
UNSEALED RADIONUCLIDES IN THERAPY
UNSEALED RADIONUCLIDES IN DIAGNOSTICS
RADIOISOTOPE PRODUCTION